EverQuote, Inc.

Annual Trend FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Net income (loss) ($13.8m)
($7.1m) +48.39%
($11.2m) -57.40%
($19.4m) -73.49%
($24.4m) -25.64%
($51.3m) -110.05%
$32.2m +162.72%
$99.3m +208.72%
Depreciation and amortization expense $1.3m $2.2m $3.4m $5.1m $5.8m $6.2m $5.7m $3.8m $3.4m
Depreciation Amortization Depletion $5.8m $6.2m $5.7m $3.8m $3.4m
Deferred taxes ($2.5m) $0 $0 $0 ($38.4m)
Deferred Income Tax $0 $0 $0 ($38.4m) ($30.4m)
Stock-based compensation expense $7.1m $12.7m $24.2m $30.0m $29.0m $24.1m $20.6m $24.3m $23.1m
Impairment of right-of-use asset $384k
Asset Impairment Charge $0 $384k $0 $0 $0
Change In Working Capital ($22.8m) ($1.7m) $8.1m ($1.6m) ($9.9m)
Accounts receivable ($2.8m) ($15.2m) ($14.0m) $10.5m $5.4m $8.2m ($40.2m) ($13.8m) ($21.1m)
Change In Receivables ($18.9m) $12.4m ($35.3m) ($11.9m) ($21.1m)
Changes In Account Receivables $5.4m $8.2m ($40.2m) ($13.8m) ($21.1m)
Accounts payable $4.9m $6.8m $9.3m ($4.0m) $1.1m ($13.4m) $42.7m $16.9m $11.3m
Acquisition of property and equipment included in accounts payable $3.7m $3.0m $3.8m $100k $60k $25k $135k $125k
Change In Payables And Accrued Expense ($1.3m) ($15.0m) $43.7m $14.8m $11.3m
Accrued expenses and other current liabilities $1.3m $10.1m ($4.0m) $2.7m ($2.4m) ($1.5m) $1.0m ($2.1m)
Deferred revenue $454k $61k $368k $227k ($229k) $5k ($107k) ($103k)
Change In Accrued Expense ($2.4m) ($1.5m) $1.0m ($2.1m) $2.6m
Prepaid expenses and other current assets ($863k) ($5.6m) $623k ($3.6m) ($2.1m) $962k $440k ($4.4m)
Other assets ($1k) ($554k) ($10.9m) ($19k) $421k ($291k) $137k
Change In Other Current Assets $2.6m $2.9m $1.9m $1.3m $1.3m
Change In Other Current Liabilities ($2.9m) ($3.0m) ($2.5m) ($1.1m) ($1.2m)
Net cash provided by (used in) operating activities ($1.9m)
$4.4m +332.63%
$10.7m +141.74%
$7.2m -32.61%
($15.8m) -319.66%
($2.8m) +82.09%
$66.6m +2453.82%
$95.4m +43.29%
$100.7m +5.58%
Acquisition of property and equipment, including costs capitalized for development of internal-use software ($3.7m) ($3.0m) ($3.8m) ($2.9m) ($4.3m) ($3.8m) ($4.1m) ($5.1m)
Capital Expenditure ($4.3m) ($3.8m) ($4.1m) ($5.1m) ($5.6m)
Net cash provided by (used in) investing activities ($3.7m) ($3.0m) ($18.8m) ($18.8m) ($4.3m) $9.4m ($4.1m) ($5.1m) ($5.6m)
Provision for bad debt $478k $105k ($41k) $693k $204k $13k $10k
Repurchase of common stock ($21.0m)
Proceeds from private placement of common stock $15.0m
Issuance of Class A common stock $2.1m
Common Stock Issuance $0 $15.0m $0 $0 ($21.0m) $0
Common Stock Payments $0 $0 ($21.0m) ($50.0m)
Issuance Of Capital Stock $0 $15.0m $0 $0 $0
Repurchase Of Capital Stock $0 $0 ($21.0m) ($50.0m)
Tax withholding payments related to net share settlement ($100k) ($402k) ($1.8m) ($4.0m)
Net Other Financing Charges ($100k) ($402k) ($1.8m) ($4.0m) ($3.6m)
Net cash provided by (used in) financing activities $44.8m
$3.0m -93.35%
$4.9m +64.55%
$3.6m -26.33%
$15.8m +338.23%
$577k -96.36%
$1.7m +195.84%
($21.1m) -1333.98%
($51.0m) -142.13%
Cash, cash equivalents and restricted cash at beginning of period $41.9m $46.3m $43.1m $35.1m $30.8m $38.0m $102.1m $171.4m
Beginning Cash Position $35.1m $30.8m $38.0m $102.1m $148.2m
Effect of exchange rate changes on cash, cash equivalents and restricted cash ($7k) ($6k) ($27k) $18k $1k $3k ($3k)
Net increase in cash, cash equivalents and restricted cash $39.3m $4.4m ($3.2m) ($8.0m) ($4.3m) $7.1m $64.2m $69.3m
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Loss on sale of health assets $19.4m
Change in fair value of contingent consideration liabilities $1.8m $196k ($4.1m) ($150k)
Unrealized foreign currency transaction (gains) losses $24k ($9k) $21k ($26k) $110k
Litigation accrual settled with sale of assets $7.8m
Commissions receivable, current and non-current ($5.8m) ($16.9m) ($24.2m) $4.2m $4.9m $1.9m
Operating lease right-of-use assets $2.1m $2.7m $2.6m $2.5m $2.2m $1.1m
Operating lease liabilities ($2.2m) ($2.8m) ($2.9m) ($3.0m) ($2.5m) ($1.1m)
Proceeds from sale of health assets $13.2m
Proceeds from exercise of stock options $861k $3.0m $4.9m $3.6m $942k $979k $3.6m $3.9m
Assets sold in settlement of litigation accrual $8.1m
Operating lease liabilities arising from obtaining right-of-use assets $541k $383k $1.1m $0 $4.0m $0
Cash Flow From Continuing Financing Activities $15.8m $577k $1.7m ($21.1m) ($51.0m)
Cash Flow From Continuing Investing Activities ($4.3m) $9.4m ($4.1m) ($5.1m) ($5.6m)
Change In Account Payable $1.1m ($13.4m) $42.7m $16.9m $11.3m
Change In Cash Supplemental As Reported ($4.3m) $7.1m $64.2m $69.3m
Change In Other Working Capital ($229k) $5k ($107k) ($103k) $179k
Change In Payable $1.1m ($13.4m) $42.7m $16.9m $11.3m
Change In Prepaid Assets ($2.1m) $962k $440k ($4.4m) ($3.0m)
Changes In Cash ($4.2m) $7.1m $64.2m $69.3m $44.1m
End Cash Position $30.8m $38.0m $102.1m $171.4m $192.3m
Financing Cash Flow $15.8m
$577k -96.36%
$1.7m +195.84%
($21.1m) -1333.98%
($51.0m) -142.13%
Free Cash Flow ($20.1m) ($6.7m) $62.5m $90.3m $95.1m
Income Tax Paid Supplemental Data $175k $589k $2.3m $2.3m
Investing Cash Flow ($4.3m) $9.4m ($4.1m) ($5.1m) ($5.6m)
Net Business Purchase And Sale ($16.0m) $0 $0
Net Foreign Currency Exchange Gain Loss ($9k) $21k ($26k) $110k ($37k)
Net PPE Purchase And Sale ($4.3m) ($3.8m) ($4.1m) ($5.1m) ($5.6m)
Operating Gains Losses ($9k) $19.4m ($26k) $110k ($37k)
Other Non Cash Items $196k ($4.1m) ($150k) $7.8m
Proceeds From Stock Option Exercised $942k $979k $3.6m $3.9m $2.6m
Provisionand Write Offof Assets $693k $204k $13k $10k $5k
Purchase Of Business ($16.0m) $0 $0
Purchase Of PPE $3.7m $3.0m $3.8m $2.9m ($4.3m) ($3.8m) ($4.1m) ($5.1m) ($5.6m)
Stock Based Compensation $29.0m $24.1m $20.6m $24.3m $23.1m